REGENERON PHARMACEUTICALS (REGN) Stock Fundamental Analysis

NASDAQ:REGN • US75886F1075

803.17 USD
+19.52 (+2.49%)
At close: Feb 13, 2026
797.567 USD
-5.6 (-0.7%)
After Hours: 2/13/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to REGN. REGN was compared to 523 industry peers in the Biotechnology industry. REGN gets an excellent profitability rating and is at the same time showing great financial health properties. REGN is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • REGN had positive earnings in the past year.
  • In the past year REGN had a positive cash flow from operations.
  • REGN had positive earnings in each of the past 5 years.
  • Of the past 5 years REGN 4 years had a positive operating cash flow.
REGN Yearly Net Income VS EBIT VS OCF VS FCFREGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

1.2 Ratios

  • REGN has a better Return On Assets (11.40%) than 94.07% of its industry peers.
  • REGN has a better Return On Equity (14.79%) than 94.46% of its industry peers.
  • REGN has a better Return On Invested Capital (9.87%) than 94.65% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for REGN is significantly below the industry average of 18.27%.
Industry RankSector Rank
ROA 11.4%
ROE 14.79%
ROIC 9.87%
ROA(3y)11.58%
ROA(5y)16.27%
ROE(3y)14.89%
ROE(5y)21.37%
ROIC(3y)11.38%
ROIC(5y)18.13%
REGN Yearly ROA, ROE, ROICREGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

1.3 Margins

  • Looking at the Profit Margin, with a value of 32.13%, REGN belongs to the top of the industry, outperforming 96.56% of the companies in the same industry.
  • REGN's Profit Margin has declined in the last couple of years.
  • REGN has a Operating Margin of 27.61%. This is amongst the best in the industry. REGN outperforms 96.56% of its industry peers.
  • In the last couple of years the Operating Margin of REGN has declined.
  • REGN has a Gross Margin of 86.28%. This is amongst the best in the industry. REGN outperforms 88.91% of its industry peers.
  • In the last couple of years the Gross Margin of REGN has remained more or less at the same level.
Industry RankSector Rank
OM 27.61%
PM (TTM) 32.13%
GM 86.28%
OM growth 3Y-15.55%
OM growth 5Y-9.14%
PM growth 3Y-4.13%
PM growth 5Y-5.35%
GM growth 3Y-1.5%
GM growth 5Y-0.34%
REGN Yearly Profit, Operating, Gross MarginsREGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • REGN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, REGN has less shares outstanding
  • Compared to 5 years ago, REGN has less shares outstanding
  • Compared to 1 year ago, REGN has an improved debt to assets ratio.
REGN Yearly Shares OutstandingREGN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
REGN Yearly Total Debt VS Total AssetsREGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

2.2 Solvency

  • An Altman-Z score of 7.67 indicates that REGN is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of REGN (7.67) is better than 78.59% of its industry peers.
  • REGN has a debt to FCF ratio of 0.70. This is a very positive value and a sign of high solvency as it would only need 0.70 years to pay back of all of its debts.
  • The Debt to FCF ratio of REGN (0.70) is better than 94.65% of its industry peers.
  • A Debt/Equity ratio of 0.09 indicates that REGN is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.09, REGN is doing worse than 61.57% of the companies in the same industry.
  • Even though the debt/equity ratio score it not favorable for REGN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 0.7
Altman-Z 7.67
ROIC/WACC0.81
WACC12.21%
REGN Yearly LT Debt VS Equity VS FCFREGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

2.3 Liquidity

  • A Current Ratio of 4.06 indicates that REGN has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 4.06, REGN is in line with its industry, outperforming 48.76% of the companies in the same industry.
  • A Quick Ratio of 3.51 indicates that REGN has no problem at all paying its short term obligations.
  • The Quick ratio of REGN (3.51) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.06
Quick Ratio 3.51
REGN Yearly Current Assets VS Current LiabilitesREGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • REGN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.76%.
  • The Earnings Per Share has been growing slightly by 6.99% on average over the past years.
  • REGN shows a small growth in Revenue. In the last year, the Revenue has grown by 0.99%.
  • REGN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.04% yearly.
EPS 1Y (TTM)-2.76%
EPS 3Y1.53%
EPS 5Y6.99%
EPS Q2Q%-5.22%
Revenue 1Y (TTM)0.99%
Revenue growth 3Y5.62%
Revenue growth 5Y11.04%
Sales Q2Q%2.51%

3.2 Future

  • REGN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.05% yearly.
  • The Revenue is expected to grow by 7.10% on average over the next years.
EPS Next Y4.68%
EPS Next 2Y11.02%
EPS Next 3Y11.23%
EPS Next 5Y10.05%
Revenue Next Year9.08%
Revenue Next 2Y9.41%
Revenue Next 3Y8.95%
Revenue Next 5Y7.1%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
REGN Yearly Revenue VS EstimatesREGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B 20B
REGN Yearly EPS VS EstimatesREGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20 40 60

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 18.10 indicates a rather expensive valuation of REGN.
  • Compared to the rest of the industry, the Price/Earnings ratio of REGN indicates a rather cheap valuation: REGN is cheaper than 95.41% of the companies listed in the same industry.
  • REGN is valuated rather cheaply when we compare the Price/Earnings ratio to 27.97, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 17.29, REGN is valued on the expensive side.
  • Based on the Price/Forward Earnings ratio, REGN is valued cheaply inside the industry as 94.84% of the companies are valued more expensively.
  • REGN is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 27.96, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 18.1
Fwd PE 17.29
REGN Price Earnings VS Forward Price EarningsREGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • REGN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. REGN is cheaper than 95.22% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of REGN indicates a rather cheap valuation: REGN is cheaper than 95.03% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 21.75
EV/EBITDA 15.85
REGN Per share dataREGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 50 100 150 200 250

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • REGN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)3.87
PEG (5Y)2.59
EPS Next 2Y11.02%
EPS Next 3Y11.23%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

2

5. Dividend

5.1 Amount

  • With a yearly dividend of 0.49%, REGN is not a good candidate for dividend investing.
  • REGN's Dividend Yield is rather good when compared to the industry average which is at 1.14. REGN pays more dividend than 98.28% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.79, REGN's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.49%

5.2 History

  • REGN does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
REGN Yearly Dividends per shareREGN Yearly Dividends per shareYearly Dividends per share 2025 2026 1 2 3

5.3 Sustainability

DPN/A
EPS Next 2Y11.02%
EPS Next 3Y11.23%
REGN Yearly Income VS Free CF VS DividendREGN Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

Find the best dividend stocksShow peers with best dividend

REGENERON PHARMACEUTICALS

NASDAQ:REGN (2/13/2026, 8:00:01 PM)

After market: 797.567 -5.6 (-0.7%)

803.17

+19.52 (+2.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-30
Earnings (Next)04-27
Inst Owners90.13%
Inst Owner Change-1.56%
Ins Owners1.95%
Ins Owner Change3.45%
Market Cap84.41B
Revenue(TTM)14.34B
Net Income(TTM)4.58B
Analysts79.44
Price Target862.4 (7.37%)
Short Float %2.26%
Short Ratio2.4
Dividend
Industry RankSector Rank
Dividend Yield 0.49%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date02-20
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.37%
Min EPS beat(2)20.96%
Max EPS beat(2)49.77%
EPS beat(4)3
Avg EPS beat(4)16.75%
Min EPS beat(4)-8.66%
Max EPS beat(4)49.77%
EPS beat(8)6
Avg EPS beat(8)9.92%
EPS beat(12)10
Avg EPS beat(12)9.47%
EPS beat(16)13
Avg EPS beat(16)8.82%
Revenue beat(2)2
Avg Revenue beat(2)6.19%
Min Revenue beat(2)2.66%
Max Revenue beat(2)9.72%
Revenue beat(4)2
Avg Revenue beat(4)0.54%
Min Revenue beat(4)-9.31%
Max Revenue beat(4)9.72%
Revenue beat(8)4
Avg Revenue beat(8)0.34%
Revenue beat(12)8
Avg Revenue beat(12)1.48%
Revenue beat(16)12
Avg Revenue beat(16)2.04%
PT rev (1m)6.7%
PT rev (3m)15.32%
EPS NQ rev (1m)0.22%
EPS NQ rev (3m)2.51%
EPS NY rev (1m)0.85%
EPS NY rev (3m)4.59%
Revenue NQ rev (1m)0.88%
Revenue NQ rev (3m)0.96%
Revenue NY rev (1m)2.47%
Revenue NY rev (3m)4.54%
Valuation
Industry RankSector Rank
PE 18.1
Fwd PE 17.29
P/S 5.92
P/FCF 21.75
P/OCF 16.65
P/B 2.73
P/tB 2.85
EV/EBITDA 15.85
EPS(TTM)44.38
EY5.53%
EPS(NY)46.46
Fwd EY5.78%
FCF(TTM)36.93
FCFY4.6%
OCF(TTM)48.25
OCFY6.01%
SpS135.56
BVpS294.56
TBVpS281.42
PEG (NY)3.87
PEG (5Y)2.59
Graham Number542.34
Profitability
Industry RankSector Rank
ROA 11.4%
ROE 14.79%
ROCE 11.01%
ROIC 9.87%
ROICexc 12.92%
ROICexgc 13.61%
OM 27.61%
PM (TTM) 32.13%
GM 86.28%
FCFM 27.24%
ROA(3y)11.58%
ROA(5y)16.27%
ROE(3y)14.89%
ROE(5y)21.37%
ROIC(3y)11.38%
ROIC(5y)18.13%
ROICexc(3y)19.35%
ROICexc(5y)27.21%
ROICexgc(3y)20.67%
ROICexgc(5y)28.27%
ROCE(3y)12.69%
ROCE(5y)20.22%
ROICexgc growth 3Y-3.7%
ROICexgc growth 5Y-3.85%
ROICexc growth 3Y-4.84%
ROICexc growth 5Y-5.51%
OM growth 3Y-15.55%
OM growth 5Y-9.14%
PM growth 3Y-4.13%
PM growth 5Y-5.35%
GM growth 3Y-1.5%
GM growth 5Y-0.34%
F-Score5
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 0.7
Debt/EBITDA 0.61
Cap/Depr 226.62%
Cap/Sales 8.35%
Interest Coverage 250
Cash Conversion 113.73%
Profit Quality 84.78%
Current Ratio 4.06
Quick Ratio 3.51
Altman-Z 7.67
F-Score5
WACC12.21%
ROIC/WACC0.81
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.76%
EPS 3Y1.53%
EPS 5Y6.99%
EPS Q2Q%-5.22%
EPS Next Y4.68%
EPS Next 2Y11.02%
EPS Next 3Y11.23%
EPS Next 5Y10.05%
Revenue 1Y (TTM)0.99%
Revenue growth 3Y5.62%
Revenue growth 5Y11.04%
Sales Q2Q%2.51%
Revenue Next Year9.08%
Revenue Next 2Y9.41%
Revenue Next 3Y8.95%
Revenue Next 5Y7.1%
EBIT growth 1Y-6.18%
EBIT growth 3Y-10.8%
EBIT growth 5Y0.89%
EBIT Next Year12.49%
EBIT Next 3Y19.46%
EBIT Next 5Y16.42%
FCF growth 1Y16.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.39%
OCF growth 3YN/A
OCF growth 5YN/A

REGENERON PHARMACEUTICALS / REGN FAQ

Can you provide the ChartMill fundamental rating for REGENERON PHARMACEUTICALS?

ChartMill assigns a fundamental rating of 6 / 10 to REGN.


What is the valuation status of REGENERON PHARMACEUTICALS (REGN) stock?

ChartMill assigns a valuation rating of 6 / 10 to REGENERON PHARMACEUTICALS (REGN). This can be considered as Fairly Valued.


Can you provide the profitability details for REGENERON PHARMACEUTICALS?

REGENERON PHARMACEUTICALS (REGN) has a profitability rating of 7 / 10.


What is the financial health of REGENERON PHARMACEUTICALS (REGN) stock?

The financial health rating of REGENERON PHARMACEUTICALS (REGN) is 8 / 10.